Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists at the University of Tübingen test Canadian Ebola vaccine

22.10.2014

Scientists at the Institute of Tropical Medicine, University Hospital Tübingen, Germany, are together with their partner institute CERMEL in Lambaréné, Gabon conducting a clinical trial to test an Canadian Ebola vaccine. A consortium of experts, including scientists from both institutes, was convened by the WHO in August to discuss solutions and strategies for combating the current Ebola crisis.

Of interest at this consortium was one of two forerunning Ebola vaccine candidates which have shown significant promise in animal studies, but have not yet been approved for use in humans.

The candidate VSVΔG-ZEBOV, developed in Canada and produced by the American firm NewLink Genetics is based upon an attenuated Vesicular Stomatitis Virus which has had a single gene from the Zaire Ebola virus inserted. 800 ampules of the vaccine are now provided to the WHO for the clinical trial.

Data from animal studies to date show that animals vaccinated with VSVΔG-ZEBOV are protected against infection with Ebola. Following this success, further studies in humans are warranted to establish a dosage which is safe and well tolerated, whilst simultaneously assessing immunogenicity.

... more about:
»Ebola »Ebola virus »Gabon »vaccination

This research will be conducted in institutions across the USA, Europe and Africa and the findings of the phase I study (n=60) in Gabon will be particularly interesting.

They will provide information about how well the vaccine is tolerated by people in the African population; vital for quick distribution of the vaccine in West Africa once a safe and effective dose has been established.

Coordinating doctor of the study Professor Peter Kremsner from the University Hospital in Tübingen is working towards vaccination of the first volunteer in Gabon at the beginning of November.

The first data are projected to be available in just a few weeks after the first vaccination, enabling a decision to be made about whether the vaccine can be introduced into affected West African communities and in which dose.

Press contact

Universitätsklinikum Tübingen
Medizinische Klinik, Institut für Tropenmedizin
Prof. Dr. Peter Kremsner
Wilhelmstr. 27, 72076 Tübingen
Tel. +49 7071/29-8 71 89, E-Mail peter.kremsner@uni-tuebingen.de

Dr. Ellen Katz | idw - Informationsdienst Wissenschaft
Further information:
http://www.medizin.uni-tuebingen.de/

Further reports about: Ebola Ebola virus Gabon vaccination

More articles from Health and Medicine:

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

nachricht Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>